Japan Tobacco Inc. and D-Wave Announce Collaboration Aimed at Accelerating Innovative Drug Discovery with Quantum AI
Proof-of-concept project to explore using quantum computing to revolutionize the speed and quality of “Quantum AI-driven Drug Discovery,” aimed at creating first-in-class small molecule pharmaceuticals
Supported by D-Wave's team of professional services experts, the AI team in JT’s pharmaceutical division will utilize D-Wave's annealing quantum computing solutions as accelerators in the speed and quality of training JT’s novel AI-driven analysis systems, aiming to extend the applicable range of such AI systems in the drug discovery field (AI-driven Drug Design). The goal of the project is to pioneer a new process for discovering 'first-in-class' pharmaceutical small compounds.
"In our development of AI-driven drug discovery systems, we have been focusing on and researching quantum computing technologies as a speed and quality accelerator in the drug design process,” said Dr.
"Pharmaceutical companies need to maintain competitiveness while addressing the challenges of difficulty, uncertainty, and duration in new drug development, creating an environment that is accelerating the speed and quality for AI drug discovery,” said Dr.
Following the proof-of-concept project, JT’s pharmaceutical division plans to further advance the developed, Quantum AI-driven Drug Discovery analysis systems and eventually move the application of quantum computing technology into production operations.
About JT Pharma
JT commenced its pharmaceutical business in 1987 with its mission to create original and innovative drugs for patients suffering from diseases around the world. To learn more, visit https://www.jt.com/about/division/pharma/index.html.
About
D-Wave is a leader in the development and delivery of quantum computing systems, software, and services, and is the world’s first commercial supplier of quantum computers—and the only company building both annealing quantum computers and gate-model quantum computers. Our mission is to unlock the power of quantum computing today to benefit business and society. We do this by delivering customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. D-Wave’s technology has been used by some of the world’s most advanced organizations including Mastercard, Deloitte,
Forward-Looking Statements
Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241001077960/en/
D-Wave
media@dwavesys.com
Source: